4D Molecular Therapeutics shares are trading lower. The company announced interim clinical data from the 4D-710 Phase 1/2 AEROW clinical trial for the treatment of cystic fibrosis lung disease.
Portfolio Pulse from Benzinga Newsdesk
4D Molecular Therapeutics shares are trading lower following the announcement of interim clinical data from the 4D-710 Phase 1/2 AEROW clinical trial for the treatment of cystic fibrosis lung disease.
June 06, 2024 | 12:22 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
4D Molecular Therapeutics shares are trading lower after the company announced interim clinical data from the 4D-710 Phase 1/2 AEROW clinical trial for cystic fibrosis lung disease.
The announcement of interim clinical data from the 4D-710 Phase 1/2 AEROW clinical trial has led to a decline in 4D Molecular Therapeutics shares. Investors may be reacting to the data, which could indicate concerns about the trial's progress or results.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100